<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Einstein (Sao Paulo)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Einstein (Sao Paulo)</journal-id>
      <journal-id journal-id-type="publisher-id">eins</journal-id>
      <journal-title-group>
        <journal-title>Einstein</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1679-4508</issn>
      <issn pub-type="epub">2317-6385</issn>
      <publisher>
        <publisher-name>Instituto Israelita de Ensino e Pesquisa Albert Einstein</publisher-name>
        <publisher-loc>Sao Paulo</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24728255</article-id>
      <article-id pub-id-type="pmc">4898248</article-id>
      <article-id pub-id-type="publisher-id">S1679-45082014RC2708</article-id>
      <article-id pub-id-type="doi">10.1590/S1679-45082014RC2708</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Submacular hemorrhage secondary to congenital toxoplasmosis</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Hemorragia submacular secund&#xE1;ria &#xE0; toxoplasmose cong&#xEA;nita</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Ana Luiza Fontes de Azevedo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martins</surname>
            <given-names>Thiago Gon&#xE7;alves dos Santos</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moncada</surname>
            <given-names>Francisco Javier Solano</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Motta</surname>
            <given-names>M&#xE1;rio Martins dos Santos</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Hospital Federal dos Servidores do Estado, Rio de Janeiro, RJ, Brazil</aff>
        <aff id="aff2"><label>2</label>Universidade Federal de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brazil</aff>
        <aff id="aff3"><label>3</label>Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brazil</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1">Corresponding author: Ana Luiza Fontes de Azevedo Costa &#x2013; Rua Sacadura Cabral, 178 &#x2013; Sa&#xFA;de &#x2013; Zip code: 20221-161 &#x2013; Rio de Janeiro, RJ, Brazil &#x2013; Phone: <phone>(55 21) 3228-2209</phone> &#x2013; E-mail: <email>luizafacosta@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jan-Mar</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jan-Mar</season>
        <year>2014</year>
      </pub-date>
      <volume>12</volume>
      <issue>1</issue>
      <fpage>106</fpage>
      <lpage>108</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>12</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>12</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p>
        </license>
      </permissions>
      <abstract>
        <title>ABSTRACT</title>
        <p>We report the case of a patient with congenital toxoplasmosis and submacular hemorrhage caused by a neovascular membrane who underwent an intravitreal injection of C3F8 and bevacizumab, and had a good visual recovery.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <title>RESUMO</title>
        <p>Relatamos o caso de uma paciente com toxoplasmose cong&#xEA;nita e hemorragia submacular por uma membrana neovascular submetida &#xE0; inje&#xE7;&#xE3;o intrav&#xED;trea de C3F8 e bevacizumabe, com boa recupera&#xE7;&#xE3;o visual.</p>
      </trans-abstract>
      <kwd-group>
        <title>Keywords:</title>
        <kwd>Toxoplasmosis</kwd>
        <kwd>congenital/etiology</kwd>
        <kwd>Retinal hemorrhage/etiology</kwd>
        <kwd>Intravitreal injections/adverse effects</kwd>
        <kwd>Retinal neovascularization/complications</kwd>
        <kwd>Angiogenesis inhibitors</kwd>
        <kwd>Tomography</kwd>
        <kwd>optical coherence</kwd>
        <kwd>Case reports</kwd>
      </kwd-group>
      <counts>
        <fig-count count="10"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="8"/>
        <page-count count="3"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>The retinochoroiditis is the most common manifestation of congenital toxoplasmosis that is bilateral in 50 to 80% of cases. This inflammation could also compromise the retinal vascular system and the formation of subretinal neovascular membrane, which could be seen in the edge of the lesion or distant from the edge with nourishing arteries arising from the scar.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
</p>
      <p>We report a case of patient with congenital toxoplasmosis caused by subretinial neovascular membrane with a submacular hemorrhage that, although infrequent, could promote important consequences because of the visual acuity reduction. Despite this fact, it could be treated with possibility of recovering.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>LSE, an 18-year-old student woman was admitted to the <italic>Hospital das Cl&#xED;nicas da Faculdade de Medicina da Universidade de S&#xE3;o Paulo</italic> on February 2010, with low visual acuity for 1 week. The patient was diagnosed with ocular congenital toxoplasmosis by the age 15 years old.</p>
      <p>An ophthalmologic exam performed at admission showed corrected visual acuity with counting finger from 1m in the right eye and hand motion in the left eye. The visual acuity in the left eye of the patient was 20/20 without correction, which happened before she develops the reported episode according to information collected from the medical record. In order to register and support the diagnosis a retinography and an angiofluoresceinography were conducted (<xref ref-type="fig" rid="f1">Figure 1</xref>). On February 18, 2010 the patient, in face-down position, received an intravitreal injection of 0.3mL of C3F8 in left eye.</p>
      <fig id="f1" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <title>Scar area with submacular hemorrhage in the left eye</title>
        </caption>
        <graphic xlink:href="1679-4508-eins-12-01-0106-gf01"/>
      </fig>
      <p>One day after the procedure the patient was presenting vision of 20/50 and inferior displacement of submacular hemorrhage (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p>
      <fig id="f2" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <title>First day after intravitreal injection of C3F8</title>
        </caption>
        <graphic xlink:href="1679-4508-eins-12-01-0106-gf02"/>
      </fig>
      <p>On August 25, 2010 a reduction of visual acuity to 20/200 was seen. The funduscopy revealed partial absorption of hemorrhage but with macular edema (<xref ref-type="fig" rid="f3">Figure 3</xref>). Based on this clinical feature, on March 1, 2010 an intravitreal bevacizumab injection was conducted.</p>
      <fig id="f3" orientation="portrait" position="float">
        <label>Figure 3</label>
        <caption>
          <title>One week after intravitreal injection of C3F8</title>
        </caption>
        <graphic xlink:href="1679-4508-eins-12-01-0106-gf03"/>
      </fig>
      <p>A week after this procedure the patient showed visual acuity of 20/20 in the left eye. The retinography showed a higher reduction of submacular hemorrhage and and hyperfluorescence due to impregnation of neovascular membrane without significant leakage. The optical coherence tomography found a neovascular membrane in front of pigment epithelium without significant intraretinal edema (<xref ref-type="fig" rid="f4">Figure 4</xref>).</p>
      <fig id="f4" orientation="portrait" position="float">
        <label>Figure 4</label>
        <caption>
          <title>One week after intravitreal injection of bevacizumab</title>
        </caption>
        <graphic xlink:href="1679-4508-eins-12-01-0106-gf04"/>
      </fig>
      <p>After 6 months of follow-up, the visual acuity of 20/20 in the left eye was maintained and no signs of membrane activity were found in fundoscopy, fluorescein angiography and optical coherence tomography (<xref ref-type="fig" rid="f5">Figure 5</xref>).</p>
      <fig id="f5" orientation="portrait" position="float">
        <label>Figure 5</label>
        <caption>
          <title>Six months after intravitreal injection of bevacizumab</title>
        </caption>
        <graphic xlink:href="1679-4508-eins-12-01-0106-gf05"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Choroidal neovascular membrane is a rare complication of toxoplasmic chorioretinitis related to the production of vascular endothelial growing factor.<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup>
</p>
      <p>Studies that analyzed the causes of submacular hemorrhage found that those secondary to age-related macular degeneration (ARMD) present a worse visual prognosis than those secondary to trauma, macroaneurysm or congenital toxoplasmosis.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup>
</p>
      <p>The treatment with low doses (18 to 50mg) of intravitreal tissue plasminogen activator and 0.3mL perfluoropropane followed by face-down position for 3 days, present good results in patients with submacular hemorrhage secondary to ARMD.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p>
      <p>There are studies showing that children with neovascular membrane had better visual recovery than adults.<sup>(<xref rid="B5" ref-type="bibr">5</xref>)</sup>
</p>
      <p>A study with intravitreal injection of C3F8 and bevacizumab, the same injection used in our case, reported good visual recovery, probably because it removed the blood in macular region, which decreases the toxicity to photoreceptors.<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup> The blood in macular region that come in contact with photoreceptors leads to edema of these receptors after 1 hour of bleeding and causes the destruction of external nuclear layer in 2 weeks due to toxic effects of iron in the hemoglobin.<sup>(<xref rid="B7" ref-type="bibr">7</xref>)</sup> The objective of bevacizumab use is to reduce the vascular permeability that provokes an involution of subretinal neovascular membrane.<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup>
</p>
      <p>Other method reported in the literature for treatment of submacular hemorrhage secondary to congenital toxoplasmosis, which presented good results, was the photodynamic therapy.<sup>(<xref rid="B8" ref-type="bibr">8</xref>)</sup>
</p>
    </sec>
    <sec sec-type="conclusions">
      <title>CONCLUSION</title>
      <p>Although unusual, the submacular hemorrhage must be considered in patients with congenital toxoplasmosis who already had scars and subretinal membrane with good visual acuity that evolved with sudden decrease of vision. The lack of studies comparing natural evolution of neovascular membrane secondary to toxoplasmosis scar in the eye enables to state that the best treatment for retinochoroiditis would be the one reported in this case especially for young patients with normal vision in only one eye.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Or&#xE9;fice</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>VD</given-names>
            </name>
            <name>
              <surname>Or&#xE9;fice</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <chapter-title>Toxoplasmose</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Or&#xE9;fice</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>VD</given-names>
            </name>
            <name>
              <surname>Or&#xE9;fice</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <source>Uve&#xED;tes e oncologia ocular</source>
          <edition>2a ed.</edition>
          <publisher-loc>Rio de Janeiro</publisher-loc>
          <publisher-name>Guanabara Koogan</publisher-name>
          <year>2011</year>
          <fpage>131</fpage>
          <lpage>156</lpage>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Benevento</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Jager</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Noble</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Latkany</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mieler</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Sautter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Meyers</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mets</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grassi</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Rabiah</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Boyer</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Swisher</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>McLeod</surname>
              <given-names>R</given-names>
            </name>
            <collab>Toxoplasmosis Study Group</collab>
          </person-group>
          <article-title>Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy</article-title>
          <source>Arch Ophthalmol</source>
          <year>2008</year>
          <volume>126</volume>
          <issue>8</issue>
          <fpage>1152</fpage>
          <lpage>1156</lpage>
          <pub-id pub-id-type="pmid">18695115</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berrocal</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Flynn</surname>
              <given-names>HW</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Variations in the clinical course of submacular hemorrhage</article-title>
          <source>Am J Ophthalmol</source>
          <year>1996</year>
          <volume>122</volume>
          <issue>4</issue>
          <fpage>486</fpage>
          <lpage>493</lpage>
          <pub-id pub-id-type="pmid">8862044</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Handwerger</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Blodi</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Chandra</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Olsen</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>TS</given-names>
            </name>
          </person-group>
          <article-title>Treatment of submacular hemorrhage with low-dose intravitreal tissue plasminogen activator injection and pneumatic displacement</article-title>
          <source>Arch Ophthalmol</source>
          <year>2001</year>
          <volume>119</volume>
          <issue>1</issue>
          <fpage>28</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="pmid">11146723</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uemura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Visual outcome after surgical removal of choroidal neovascularization in pediatric patients</article-title>
          <source>Arch Ophthalmol</source>
          <year>2000</year>
          <volume>118</volume>
          <issue>10</issue>
          <fpage>1373</fpage>
          <lpage>1378</lpage>
          <pub-id pub-id-type="pmid">11030819</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferraz</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Bressanim</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Morita</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>WY</given-names>
            </name>
          </person-group>
          <article-title>Inje&#xE7;&#xE3;o intrav&#xED;trea de bevacizumab e g&#xE1;s C3F8 para tratamento da hemorragia submacular secund&#xE1;riadegera&#xE7;&#xE3;o macular relacionada &#xE0; idade: relato de casos</article-title>
          <source>Arq Bras Oftalmol</source>
          <year>2010</year>
          <volume>73</volume>
          <issue>1</issue>
          <fpage>77</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="pmid">20464119</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Glatt</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Machemer</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Experimental subretinal hemorrhage in rabbits</article-title>
          <source>Am J Ophthalmol</source>
          <year>1982</year>
          <volume>94</volume>
          <issue>6</issue>
          <fpage>762</fpage>
          <lpage>773</lpage>
          <pub-id pub-id-type="pmid">7180915</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oliveira</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Reis</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Photodynamic therapy-treated choroidal neovascular membrane secondary to toxoplasmic retinochoroiditis</article-title>
          <source>Graefes Arch Clin Exp Ophthalmol</source>
          <year>2004</year>
          <volume>242</volume>
          <issue>12</issue>
          <fpage>1028</fpage>
          <lpage>1030</lpage>
          <pub-id pub-id-type="pmid">15064953</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
